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Edited by Robert BaroukiAbstract Chronic stress is closely linked to clinical depression,
which could be assessed by a chronic unpredictable mild stress
(CUMS) animal model. We present here a GC/MS-based meta-
bolic proﬁling approach to investigate neurochemical changes in
the cerebral cortex, hippocampus, thalamus, and remaining brain
tissues. Multi-criteria assessment for multivariate statistics
could identify diﬀerential metabolites between the CUMS-model
rats versus the healthy controls. This study demonstrates that the
signiﬁcantly perturbed metabolites mainly involving amino acids
play an indispensable role in regulating neural activity in the
brain. Therefore, results obtained from such metabolic proﬁling
strategy potentially provide a unique perspective on molecular
mechanisms of chronic stress.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Depression is a serious public mental but treatable problem,
aﬀecting about 12% of women and 7% of men annually in
USA [1]. It interferes often with normal feelings and behavior
in peoples daily life, and causes severe psychological pain for
the patients and their families. Current treatments for clinical
depression commonly involve psychotherapy and antidepres-Abbreviations: NMR, nuclear magnetic resonance; MS, mass spec-
trometry; GC/MS, gas chromatography/mass spectrometry; PCA,
principal component analysis; OPLS-DA, orthogonal partial least
squares project to latent structures-discriminant analysis; MCA, multi-
criteria assessment; VIP, variable importance in the projection;
CUMS, chronic unpredictable mild stress; SNS, sympathetic nervous
system; CNS, central nervous systems; HPA, hypothalamic–pituitary–
adrenocortical; ECF, ethyl chloroformate; CIJFjk, jack-knifed conﬁ-
dence interval; NAA, N-acetyl aspartate; BCAAs, branched-chain
amino acids
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doi:10.1016/j.febslet.2008.06.040sant medications. The most popular types of these antidepres-
sant drugs are selective serotonin reuptake inhibitors (SSRIs),
e.g., ﬂuoxetine, citalopram, sertraline and several others [2].
Chronic unpredictable mild stress (CUMS), a well-validated
animal model, has been used widely for studying clinical
depression as well as evaluating antidepressant eﬀects of di-
verse drugs [3,4]. Much of the work has been done successfully
in individual gene expression, protein structure and function,
as well as biochemical studies on sympathetic nervous system
(SNS), hypothalamic–pituitary–adrenocortical (HPA)-axis,
noradrenergic and immunological systems, etc. [5–10]. Re-
cently, the emerging metabonomics or metabolomics [11,12]
has gradually studied the intricate relationship between acute
and/or chronic stress and certain crucial endogenous metabo-
lites [13–17]. Such metabolic proﬁling technology has been
increasingly used as a versatile tool for the discovery of molec-
ular biomarkers in many areas such as monitoring the chemi-
cal-induced toxicity in organs, diagnosing or prognosing
clinical diseases, exploring the potential mechanism of diverse
diseases, and assessing therapeutic eﬀects of drugs [18–21].
Relying on the global metabolite changes in a given biological
species, metabol/nomics requires little or no prior knowledge
on a certain disease. Thus, it potentially provides not only a
means of verifying the fragmentary ﬁndings from a great deal
of individual previous research, but also a promising opportu-
nity to generate novel hypothesis for addressing the molecular
mechanisms of diseases, ultimately towards a comprehensive
understanding of physiopathological outcomes of an organism
in response to xenobiotic stimuli and/ or genetic modiﬁcation.
Biofuilds such as urine and plasma have been heavily used in
metabol/nomic studies because they are minimally invasive to
the animals or human and primarily reveal an overall meta-
bolic state of the given organism [22]. By comparison, the
tissue samples can oﬀer a unique perspective on localized met-
abolic information. As the brain is a highly complex system
encompassing a broad array of mutually interacting metabo-
lites with varied chemical properties and speciﬁc biological
functions, metabolic proﬁling of brain tissue samples will yield
beneﬁcial knowledge most related to neural activity of central
nervous systems (CNS) [23–25]. Yet no such study has been
fully initiated to monitor neurochemical changes in a CUMS
model.
Recent metabolic proﬁling technology has successfully
applied high-throughput analytical tools (e.g., NMR, nuclear
magnetic resonance; MS, mass spectrometry) to analyzeblished by Elsevier B.V. All rights reserved.
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(e.g., PCA, principal component analysis; PLS, partial least
squares projection to latent structures) to extract meaningful
biological information from the resultant complex and huge
data sets [26,27]. Variable selection is an important step in
multivariate analysis that can apparently enhance our under-
standing and interpretability of multivariate models and com-
monly referred to VIP statistics, loading weights, and
correlation coeﬃcients [28–30]. However, the practical use of
these methods relies mostly on the experimental designs and
purposes (e.g., animal or human studies, biomarker identiﬁca-
tion or pathway analysis), the size of samples, and preference
of researchers as well [31,32]. A strict approach for selecting
signiﬁcant and reliable variables should likely be a combina-
tion of multiple criteria. For instance, the newly proposed S-
plot combines both covariance and correlation deriving from
multivariate modeling [31]. But the exact criterion for each
method in variable selection is hitherto not addressed thor-
oughly.
The primary goal of this work is to characterize neurochem-
ical abnormalities in four discrete brain regions including cere-
bral cortex, hippocampus, thalamus, and the remaining
regions from a rat model of CUMS. We applied a gas chroma-
tography/mass spectrometry (GC/MS) technique to proﬁle the
brain tissue samples, and multi-criteria assessment (MCA) for
multivariate statistics to select reliable variables accountable
for class discrimination of metabolic proﬁles. The diﬀerential
metabolites were veriﬁed partially by qualitative and quantita-
tive analyses simultaneously. This work will not only provide a
constructive protocol in choosing the most reliable and signif-
icant metabolites associated with a certain pathophysiologicalFig. 1. Schematic ﬂowchart of the metabolic proﬁling strategy used in this s
water and derivatized with ethyl chloroformate (ECF) (Step 1). The resultan
gas chromatography/mass spectrometry (GC/MS) (Step 2). Multivariate stati
MS spectral data (Step 3). Compounds with signiﬁcant contribution to the
healthy controls were identiﬁed in discrete brain regions using GC/MS spect
reference compounds available (Step 4). Quantitative analysis of these v
calibration curves in order to accurately determine the concentrations of thestate when using metabolic proﬁling technology, but also ex-
pand our understanding of molecular mechanisms for diverse
diseases.2. Materials and methods
The schematic ﬂowchart of the metabolic proﬁling strategy used in
this study is illustrated in the Fig. 1.
2.1. Animal handling, sampling and sucrose preference test
The study was approved by national legislations of China and local
guidelines. A total of twelve eight-week-old male Sprague–Dawley
(SD) rats (n = 6 per group) was employed in this study and the animal
experiment is described in the Supporting Materials.
2.2. Sample preparation, GC/MS assay, and data acquisition and
pretreatment
The section was conducted as our previously described procedures
[33] and is provided in the Supporting Materials.
2.3. Multivariate and univariate statistics
Multivariate statistics, including unsupervised PCA and supervised
orthogonal partial least squares project to latent structures-discrimi-
nant analysis (OPLS-DA), was performed by SIMCA-P 11.0 software
(Umetrics, Umea˚, Sweden) [34,35]. The data set was mean-centered
and pareto-scaled in a columnwise manner for all the multivariate
modeling [36]. Mean centering calculates the average spectrum of the
data set and subtracts that average from each spectrum, aiming to fo-
cus on the ﬂuctuating part of data instead of the original value. Pareto
scaling weighs each variable by the square root of its standard devia-
tion, which ampliﬁes the contribution of lower concentration metabo-
lites but not to such an extent where noise produces a large
contribution. PCA technique was initially used to reduce the high
dimensional data sets into a two- or three-dimensional scores maptudy. The homogenized tissue samples were extracted using ultrapure
t derivatives were subsequently analyzed by a hyphenated technique –
stics was applied to extract meaningful information in the complex GC/
variation of metabolic proﬁles between the CUMS-induced rats and
ral libraries including Wiley, NIST, NBS, etc., and further veriﬁed by
eriﬁed metabolites was ﬁnally conducted by means of conventional
se metabolites in each brain region (Step 5).
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was used for investigating natural interrelation including possible
groupings, clustering, and outliers among observations.
Furthermore, a more sophisticated OPLS-DA model was achieved
through removing the variation in X matrix unrelated to Y matrix
so that the speciﬁc discriminant information between classes can
be interpreted using one predictive component alone [34,37]. Great
eﬀorts have been made to test the reliability of multivariate models
[38,39], hence the 6-round cross-validation in SMICA-P software
was herein applied to validate the OPLS-DA model against over-ﬁt-
ting by precluding 1/6th of all the samples in each round. The cross-
validated OPLS-DA scores map depicts the between-class separation
(tp) and predictive ability (Q
2Y) simultaneously [32]. Each individual
in this map is represented by two spatial dots: one for model score
value (tp) and the other for cross-validated score value (tcv). A smal-
ler diﬀerence between the two score values suggests a better predic-
tive accuracy (Q2Y).
Additionally, unpaired students t-test implemented in Microsoft Of-
ﬁce Excel 2007 (Microsoft (China) Co., Ltd. Beijing, China) was used
to determine if the discriminant score values or the concentrations of
the diﬀerential metabolites obtained from OPLS-DA modeling are sta-
tistically signiﬁcant between classes at a univariate analysis level. The
threshold of P value was set at 0.05 throughout the study.
2.4. Variable selection in OPLS-DA model
The main purpose and procedure of variable selection is illustrated
in the Fig. 2. Variable importance in the projection (VIP) ranks the
overall contribution of each variable to the OPLS-DA model, and
those variables with VIP > 1.0 are considered statistically signiﬁcant
in this model. Herein, VIP statistics was initially applied to obtain
the signiﬁcant variables that could be used for metabolic pathway
analysis [30]. Furthermore, MCA was used for choosing the most
signiﬁcant and reliable variables using a combination of VIP statistics,
S-plot, and jack-knifed based conﬁdence interval. S-plot combines the
contribution/covariance (Cov(t,X)) and reliability/correlation (Corr(t,
X)) from OPLS-DA model and helps to identify diﬀerential metabo-
lites between classes [32]. Both of these two parameters have a theoret-
ical minimum of 1 and maximum of 1. With a signiﬁcance level of
0.05, a correlation coeﬃcient (Corr(t,X)) of ±0.58 was adopted as a
cutoﬀ value to select the variables that are most correlated with the
OPLS-DA discriminant scores (predictive component). The correlation
coeﬃcients were calculated using Pearson linear correlation coeﬃcients
incorporated in MATLAB R2007a (The MathWorks, Inc., Natick,
MA, USA. Details are available in the Supplementary Materials).
The loading plot with CIJFjk displayed the uncertainty of each variable
and the smaller span of conﬁdence interval renders more creditability
on the selected variable. In this study, those variables with CIJFjk
across zero were excluded. Therefore, we merely chose those variablesFig. 2. General purpose and procedure of variable selection. VIP
statistics (VIP > 1.0) was initially opted to select the signiﬁcant
variables for biological pathway analysis while multi-criteria assess-
ment (MCA) was used for choosing the most signiﬁcant and reliable
variables (candidate biomarkers) by using a combination of VIP
statistics, S-plot, and jack-knifed based conﬁdence interval.meeting the threefold criteria (i.e., VIP > 1, |Corr(t,X)| > 0.58, and the
span of CIJFjk excluding zero) as the most signiﬁcant and reliable vari-
ables, which could serve as candidate biomarkers for CUMS.
2.5. Qualitative and quantitative analyses [40]
Compound identiﬁcation was processed by comparison of the ion
fragments with those present directly in the GC/MS spectral databases
including NIST, Wiley, and NBS, ultimately veriﬁed by reference com-
pounds available. Additionally, the concentration of each veriﬁed
metabolite was quantiﬁed via the corresponding calibration curve
and was expressed as the relative percentage change. More details
are provided in the Supporting Materials.3. Results
3.1. Sucrose preference test and body weight gain
The CUMS-treated rats consumed signiﬁcantly less sucrose
solution as compared to the healthy controls (66 ± 8% versus
96 ± 4%, P < 0.01, unpaired t-test), indicating depressive-like
behavioral state (e.g., impairment of hedonic reactivity) in
the stressed rats. Meanwhile, the CUMS-treated rats suﬀered
signiﬁcantly slower body weight gain than the healthy ones
(45.8 ± 8.7 g versus 78.2 ± 4.0 g, P < 0.05). Details are avail-
able in the Supplementary Materials. All these ﬁndings con-
ﬁrmed the stress-related eﬀects on the rat.
3.2. GC/MS spectra of brain tissue samples
Typical GC/MS total ion current (TIC) chromatograms of
each part of brain tissue samples from the CUMS-treated rats
(Supporting Fig. 1a–d) and the healthy rats (Supporting Fig.
1e–h) are illustrated. Visual inspection of these spectra re-
vealed obvious diﬀerence either among discrete brain regions
or between the CUMS-treated group versus the healthy con-
trol for each brain region, but the complexity of GC/MS spec-
tra hampered further comparison between classes. Thus, we
used our custom GC/MS analytical protocol in conjunction
with peak deconvolution procedure [29], and obtained a
three-dimensional matrix consisting of 48 samples, 161 peak
indices (RT-M/Z pairs) presumably representing individual
metabolites throughout all the tissue samples, and 161 peak
intensity. The resulting data set was subsequently analyzed
to extract useful information by multivariate statistics includ-
ing PCA and OPLS-DA.
3.3. Multivariate statistics
A ﬁve-component PCA model was initially obtained from
the GC/MS data set deriving from all the tissue samples (Table
1, Supporting Fig. 2a and b). The inherent metabolic diﬀerence
among brain regions and in relation to stress factors can be re-
ﬂected by a 2D-PCA scores plot (PC1 versus PC3, Fig. 3). In
this map, metabolic proﬁles of cerebral cortex and thalamus
can be clearly separated from those of hippocampus and the
remaining brain regions by the PC1 either in the CUMS-trea-
ted rats or in the healthy controls, while the stress-related met-
abolic variation was also readily noticed in the PC3. These
ﬁndings mostly suggested that metabolic variations depicted
by the PCA scores map were correlated with brain tissue re-
gions and stress state as well. To gain more insights into
stress-related metabolic variations in each brain compartment,
the initial data set was divided into four subsets according to
topographical region. The model quality was summarized in
the Table 1.
Table 1
Summary of the parameters for assessing modeling quality
PCA model OPLS-DA model
Noc R2Xcum
a Noc R2Xcum
a R2Ycum
a Q2Ycum
a
Cerebral cortex 3 0.65 1P + 1Ob 0.40 0.96 0.71
Hippocampus 3 0.76 1P + 1O 0.64 0.97 0.85
Thalamus 3 0.75 1P + 1O 0.45 0.98 0.78
Remaining regions 3 0.64 1P + 1O 0.45 0.91 0.60
All tissue samples 5 0.67
aR2Xcum and R
2Ycum are the cumulative modeled variation in X and Y matrix, respectively, and Q
2Ycum is the cumulative predicted variation in Y
matrix. The values of these parameters close to 1.0 indicate a robust mathematical model with a reliable predictive accuracy.
b1P + 1O, one predictive component and one orthogonal Component for establishing the OPLS-DA model.
cNo, the number of components.
Fig. 3. (a) PCA scores map of GC/MS data derived from brain tissue samples in the CUMS-treated group and the healthy control. C, cerebral
cortex; H, hippocampus; T, thalamus; R, the remaining brain regions; N, the healthy control group; and M, the CUMS-treated group. Each dot
denotes an individual rat. (b) Typical GC/MS total ion current (TIC) chromatogram of cerebral cortex from a healthy rat. The keys are provided in
the Table 2.
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A 3D-PCA scores map showed that obvious separation of
metabolic proﬁles between the CUMS-treated group and the
healthy control occurred in the PC1 (Fig. 4a). The inter-class
variation as indicated by the PCA map was also veriﬁed by
the complete and signiﬁcant separation (P < 0.01) in a cross-
validated OPLS-DA score map (Fig. 4b). Additionally, the
higher overlap between cross-validated scores (t[1]cv, i; i = 1–
6) and the model scores (t[1]p) for most of cerebral cortex sam-
ples suggested the stability and reliability of the OPLS-DA
model.
To identify which variables are accountable for such signif-
icant separation, VIP statistics was ﬁrstly used to pre-select
variables (Fig. 5a). According to the criterion for VIP statistics
(VIP > 1), a total of 28 variables were obtained for their most
contribution in discriminating metabolic proﬁles between the
two classes. Subsequently, relying on the MCA strategy includ-
ing VIP > 1, |Corr(t,X)| > 0.58, and the span of CIJFjk exclud-
ing zero, 17 variables presumably representing individual
metabolites could be considered as candidate biomarkers
(Fig. 5a–c, Table 2). For example, N-acetyl aspartate (NAA)Fig. 4. (a) 3D-PCA scores map and (b) 1D cross-validated OPLS-DA score
from the CUMS-treated group versus the healthy control group (n = 6 per g
score value (t[1]cv,6), and orthogonal score value (t[2]o) for each individualwas labeled with a red arrow in the VIP plot, S-plot, and load-
ing plot with CIJFjk. NAA has the top VIP value of 5.4, which
means that NAA contributed most for class discrimination. In
the S-plot, NAA displayed the highest positive correlation
coeﬃcient (Corr(t,X) = 0.77) and was therefore reliable for
class separation. Similar information was shown by CIJFjk
plot where NAA had a smaller span of conﬁdence interval.
Thus, NAA was surely selected for further investigation of bio-
logical signiﬁcance.
3.5. Hippocampus, thalamus, and the remaining brain tissues
GC/MS spectral datasets deriving from other three discrete
brain regions were processed in a similar manner. Each 3D-
PCA scores map showed clear separation tendency of meta-
bolic proﬁles between the CUMS-treated group and the
healthy control (Supporting Fig. 3a–c). Three additional
OPLS-DA models conﬁrmed the class separation for each
brain region according to the pathophysiological status and
the cross-validated OPLS-DA scores map indicated the stabil-
ity and reliability of each OPLS-DA model (Supporting Fig.
3d–f).map of GC/MS data deriving from cerebral cortex samples obtained
roup). The modeled score value (t[1]p), the 6th round cross-validated
are illustrated for each observation.
Fig. 5. VIP plot (a), S-plot (b), and loading plot with CIJFjk (c) from OPLS-DA modeling of GC/MS spectral data deriving from all the cerebral
cortex samples.
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tissues
Based on MCA for OPLS-DA of four discrete brain regions,
a total of 43 signiﬁcant variables were ﬁnally obtained. Amongthose signiﬁcant variables, 24 metabolites were readily identi-
ﬁed by comparing the ion fragments with those from our
GC/MS spectral databases (Table 2), and 14 amino acids were
veriﬁed using reference compounds available. Furthermore, in
Table 2
A list of signiﬁcant compounds accountable for class discrimination
Key Compound C H T R Metabolic function
1 Lactate ﬂ*n – ﬂ*n – Glucose metabolism
2 Imidazole-4-acetate ›*n ﬂ – ﬂ Histamine metabolism
3 Methylimidazole acetate ›*n › – ﬂ* Histamine metabolism
4 Alaninea ﬂ*n ›* ﬂ* › Aspartate metabolism
5 Glycinea › ›* ›*n ›n Inhibitory neurotransmitter
6 Valinea – ›*n ›*n ›*n Glutamate synthesis
7 Serine ﬂ ﬂn ›*n › Glycine metabolism
8 Leucinea – ›*n › ›*n Glutamate synthesis
9 Iso-leucinea – – – › Glutamate synthesis
10 Threoninea › – ›*n › Glycine metabolism
11 Prolinea – ›*n – ›*n Proline metabolism
12 Asparaginea ﬂ*n – – – Aspartate metabolism
13 N-Acetyl aspartate ›*n ›*n ﬂ*n ﬂ*n Aspartate metabolism
14 3-Indolepropionate – ﬂ*n – – Amino acid metabolism
15 Aspartatea ﬂ › ﬂ – Excitatory neurotransmitter
16 Methioninea – – – ›*n Cysteine metabolism
17 Glutamatea – ›*n ﬂ ﬂ* Excitatory neurotransmitter
18 Glutamine ﬂ*n ﬂn – – Glutamate metabolism
19 Phenylalaninea ›*n ›*n ›*n ›*n Tyrosine metabolism
20 Cysteine ›*n – – ﬂ Cysteine metabolism
21 Hexadecanoic acid – – › ﬂn Fatty acid biosynthesis
22 Lysinea – ﬂ*n ›n › Amino acid metabolism
23 Arachidonic acid – – ›*n – Lipid metabolism
24 Tryptophana ›*n – ›*n – Serotonin metabolism
The star (*) represents the |Corr(t,X)| > 0.58 and the triangle (n) means the span of CIJFjk excluding zero. The short dash line (–) indicates no
signiﬁcant variation. The raw data are provided in the Supplementary Materials. Abbreviations: C, cerebral cortex; H, hippocampus; T, thalamus;
and R, the remaining brain regions.
aThese metabolites are veriﬁed by reference compounds available. The arrow denotes the VIP value greater than 1.0 and the up- (or down-)
regulation of the arrow represents the relative increased (or decreased) concentration in the CUMS-treated group as compared to the healthy control.
Table 3
Relative percentage of variation for 14 amino acids using quantitative
analysis
Key Compound C H T R
4 Alanine ﬂ23%* ﬂ18%a – –
5 Glycine – – ›13% ›24%
6 Valine – – ›18% ›70%*
8 Leucine ﬂ18% ›13%* ›13% ›57%*
9 Iso-leucine – – ›29%* ›67%*
10 Threonine ﬂ14%a – ›38% ›22%*
11 Proline ﬂ13% – – ›19%
12 Asaparagine ﬂ44%* – – ›34%
15 Aspartate ﬂ13%* – – –
16 Methionine – ›18% – ›23%
17 Glutamate – – – ›16%a
19 Phenylalanine – – ›20% ›37%*
22 Lysine ﬂ22% ﬂ24% ›23% ›37%
24 Tyrptophan – ﬂ15% ›33%* –
aInconsistency with multivariate statistics.
*Statistical signiﬁcance (P < 0.05, unpaired students t-test).
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crete brain regions, quantitative analysis was carried out on
these 14 amino acids. The accurate percentage of these metab-
olites was calculated (Table 3).4. Discussion
With the aim of monitoring the local metabolic changes in
complex neural disorder–chronic unpredictable mild stress,
we used a GC/MS technique to proﬁle the metabolites present
in four discrete brain regions, including cerebral cortex, hippo-campus, thalamus, and the remaining regions in the rats ex-
posed repeatedly to nine diﬀerent stressors for four weeks in
a random order. Cerebral cortex is the largest part of the brain
related with sophisticated brain functions such as thought and
action; thalamus and hippocampus are important parts in the
limbic system, which is associated with emotional reactions
and has been an interest in clinical depression research. Thus,
we focused on those four distinct brain regions for their spe-
ciﬁc biological functions. To our great interest, not all the met-
abolic variations occur consistently in the four brain regions in
this study. For instance, lactate, as one major end product of
both aerobic and anaerobic glycolysis [41], was found signiﬁ-
cantly decreased only in cerebral cortex and thalamus with
sensory and motor functions. Such abnormal alteration might
indicate that energy metabolism in cortex and thalamus was an
outcome of long-time fatigue of CUMS-treated rats in our
study. In terms of biological functions in other brain regions,
a more systematic study involving molecular biology is needed
to investigate the biochemical variations of each brain region
in the future work.
4.1. Identiﬁcation of signiﬁcant metabolites
Relying on the four subsets of signiﬁcant metabolites, many
metabolites signiﬁcantly altered between the CUMS-treated
group and the healthy control in a certain brain region but
did not feature across all the brain regions whereas some dif-
ferential metabolites did not display consistent changing trend
across diﬀerent brain regions. Despite of such inconsistence,
the disturbed metabolic pathways, particularly disorder of
amino acid metabolism, could be prominently reﬂected in the
brain [42] (Fig. 6).
Fig. 6. The perturbed metabolic pathways especially amino acid metabolism in the stress-rats. Compound detected in this study was shown in bond
italic font.
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According to the MCA measure, a number of 14 amino
acids was identiﬁed and quantiﬁed, which is considered as
the most signiﬁcant and reliable metabolites closely associated
with CUMS. Quantitative analysis not only provides accu-
rately subtle metabolic variation in the brain tissues but also
can assess the ﬁndings from multivariate statistics. Taking into
consideration that various factors, e.g., systemic errors in
weighing, extraction, and derivatization of tissue samples pos-
sibly interfered with the stress-related metabolic variation, we
set a minimum percentage (13%) with statistical signiﬁcance
(P < 0.05) as a critical threshold (Table 3). It is reasonable that
the concentration changes for the majority of these amino
acids are fairly consistent with the results from multivariate
statistics, except for inconsistent alteration of three com-
pounds (threonine in cerebral cortex; alanine in hippocampus;
glutamate in the remaining regions). Such inconsistency is par-
tially due to the fact that signals of impurities and confounding
noise might distort the data set during normalization and scal-
ing procedures necessary for multivariate statistics [43,44].
Therefore, the present work suggested that: (1) MCA for mul-
tivariate statistics could be an eﬃcient and robust approach for
the selection of candidate biomarker metabolites; (2) quantita-
tive analysis of signiﬁcant metabolites should be accompanied
to verify the accuracy of multivariate statistics.
4.3. Amino acid metabolism
The most signiﬁcant alterations attributed to the disorder of
amino acid metabolism. These diﬀerential amino acids can be
categorized into two classes: excitatory/inhibitory neurotrans-
mitters and branched-chain amino acids (BCAAs). While the
intensity of glycine was signiﬁcantly increased across the four
brain regions, the variation of aspartate in each brain region
appeared to be inconsistent towards the stressors. Interest-ingly, the ratio of glycine to aspartate (an important inhibi-
tory/excitatory pair) was increased across all the brain regions
especially, signiﬁcantly in cortex, thalamus and the remaining
brain regions (P < 0.05), which may suggest the importance
of the intricate balance between inhibitory and excitatory ami-
no acids to maintain normal brain function [24,45]. In addi-
tion, serving as an important excitatory neurotransmitter in
the mammalian CNS, glutamate was decreased in thalamus
and the remaining brain regions but increased in hippocampus.
This ﬁnding suggested that glutamate could participate ac-
tively in the synthesis of glucose and ketone bodies for the
brain in response to xenobiotic stimuli while the excessive re-
lease of glutamate could be associated with the brain impair-
ment [46]. In parallel, the signiﬁcant reduction of glutamine
that can release amine and produce glutamate to maintain
nitrogen balance was observed in cerebral cortex and hippo-
campus. Taken together, these results may be indicative of
stress-induced deﬁciency in glutamate–glutamine neurotrans-
mitter cycling.
In this study, BCAAs including leucine, isoleucine, and va-
line, were increased in each brain region of the CUMS-induced
rats as compared to that of the healthy controls. These BCAAs
can transport quickly across the blood-brain barrier as major
amino group donors for the synthesis of brain glutamate. Re-
cent studies have demonstrated that BCAAs, especially leu-
cine, contribute most to the derivation in astrocytes of
glutamate and glutamine so as to maintain the homeostasis of
brain nitrogen [47]. Additionally, the increased concentration
of tryptophan was observed in cerebral cortex and thalamus
from the stressed rat brain. The neurotransmitter 5-hydroxy-
tryptamine (5-HT) is sensitive to the fraction of tryptophan
available in plasma for transport into the brain, as well as
the concentration of BCAAs that are transported via the
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tryptophan and BCAAs could indicate the disturbed release of
brain 5-HT that is highly related with the central fatigue [48].
Hence, the increased BCAAs and tryptophan may suggest the
impaired glutamate homeostasis in the brain as well as reﬂect
central fatigue in response to the chronic stress.
4.4. NAA metabolism
The signiﬁcant perturbation of NAA was also responsible
for discriminating metabolic proﬁles between the CUMS-trea-
ted rats and the healthy controls, showing an increase in cere-
bral cortex and hippocampus while a decrease in thalamus and
the remaining brain regions. NAA is synthesized in the mito-
chondria and considered as a marker for neuronal density
[24,49]. Generally, decrease in the concentration of NAA oc-
curs in conditions of neuronal damage or loss, such as chronic
psychosocial stress and perinatal stress [50,51]. Meanwhile, the
increase of NAA in two brain regions may reﬂect the stress-in-
duced complementary increase of amino acids for its metabolic
function of transferring amino nitrogen from the mitochon-
drion to the cytoplasm [52]. It is clear that each subtle yet sig-
niﬁcant variation of metabolites has its own biochemical
function in response to or resulting in chronic mild stress
(Table 3).
In summary, the combined use of GC/MS analytical tech-
nique and multivariate statistics facilitate the discrimination
of metabolic proﬁles in diﬀerent brain tissues including cortex,
hippocampus, thalamus, and the remaining brain regions be-
tween the CUMS-treated rats and the healthy controls. The
disorder of amino acid metabolism is signiﬁcant across all
the brain tissues, partially suggesting the impairment of neural
activity of CNS. In addition, the utility of MCA in variable
selection greatly improves reliability of the diﬀerential metab-
olites. Using this tissue-targeted metabolic proﬁling strategy,
we are able to recognize an integrated, perturbed biological
pathway-disorders of amino acid metabolism associated clo-
sely with the stress-related pathological variation in the brain.
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